Literature DB >> 26846622

Metalloproteinases 2 and 9 Immunoexpression in Periapical Lesions from Primary Endodontic Infection: Possible Relationship with the Histopathological Diagnosis and the Presence of Pain.

Isabel Schausltz Pereira Faustino1, Rebeca Souza Azevedo1, Ademar Takahama2.   

Abstract

INTRODUCTION: The aim of this study was to evaluate the possible associations among the histopathological diagnosis, the inflammatory infiltrate profile, the presence of pain, and the immunoexpression of matrix metalloproteinases MMP-2 and MMP-9 in periapical lesions from primary endodontic infection.
METHODS: Fifty-one primary periapical lesions obtained from extracted teeth were selected for this study. Patients were previously evaluated for the presence of pain and sinus tract related to the tooth to be extracted. Tissues were processed for microscopic examination and MMP-2 and MMP-9 immunoexpression. Microscopically, samples were classified as periapical granulomas or periapical cysts and the inflammatory infiltrate as chronic or mixed. The percentage of immunopositive cells for MMP-2 and MMP-9 of each case was performed based on 10 consecutive microscopic fields. The Student t or chi-square tests were used in the statistical analysis.
RESULTS: Of the total, 28 cases were classified as periapical granulomas (54.90%) and 23 cases as periapical cysts (45.10%). Seventeen patients (33.33%) reported pain associated with the extracted tooth, with 12 cases of periapical granulomas (70.58%) and 5 cases of periapical cysts (29.42%). All cases showed immunopositivity for MMP-2 and MMP-9 in a high percentage of cells, mainly in the cytoplasm of the leukocytes. MMP-2 was expressed more in periapical granulomas than periapical cysts (P < .05) and in symptomatic cases (P < .05).
CONCLUSIONS: According to the results, we may conclude that MMP-2 and MMP-9 are highly expressed in periapical lesions from a primary endodontic infection. Moreover, we may suggest MMP-2 is expressed more in periapical granuloma and in cases associated with pain.
Copyright © 2016 American Association of Endodontists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunohistochemistry; matrix metalloproteinases; pain; periapical granuloma; periapical periodontitis; radicular cyst

Mesh:

Substances:

Year:  2016        PMID: 26846622     DOI: 10.1016/j.joen.2015.12.020

Source DB:  PubMed          Journal:  J Endod        ISSN: 0099-2399            Impact factor:   4.171


  4 in total

1.  Effect of intracanal medicaments on matrix metalloproteinase-9 and vasoactive intestinal peptide secretion in periapical lesions of re-treated canals: a randomized controlled clinical study.

Authors:  Mine Büker Özdemir; Ertuğrul Karataş; Mevlüt Albayrak; Yasin Bayır
Journal:  Clin Oral Investig       Date:  2018-06-15       Impact factor: 3.573

2.  Osteoclast formation, inflammation, and matrix metalloproteinase-9 are downregulated in bone repair following root canal treatment in dogs teeth.

Authors:  Francisco Wanderley Garcia Paula-Silva; Maya Fernanda Manfrin Arnez; Giuliana de Campos Chaves Lamarque; Renato Petille; Fernanda Regina Ribeiro-Santos; Marina Fernandes de Sena; Paulo Nelson-Filho; Léa Assed Bezerra da Silva
Journal:  Clin Oral Investig       Date:  2021-01-15       Impact factor: 3.573

3.  Resveratrol Suppresses Matrix Metalloproteinase-2 Activation Induced by Lipopolysaccharide in Mouse Osteoblasts via Interactions with AMP-Activated Protein Kinase and Suppressor of Cytokine Signaling 1.

Authors:  Yaqiong Yu; Xiaolin Li; Jing Mi; Liu Qu; Di Yang; Jiajie Guo; Lihong Qiu
Journal:  Molecules       Date:  2018-09-12       Impact factor: 4.411

4.  Association between the baseline gene expression profile in periapical granuloma and periapical wound healing after surgical endodontic treatment.

Authors:  Muhammad Adeel Ahmed; Fizza Nazim; Khalid Ahmed; Muhammad Furqan Bari; Abdulaziz Abdulwahed; Ahmed A AlMokhatieb; Yaseen Alalvi; Tariq Abduljabbar; Nouman Mughal; Syed Hani Abidi
Journal:  Sci Rep       Date:  2022-08-15       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.